| Date | Title | Description |
| 23.01.2026 | ErVimmune Unlocks €17M for Groundbreaking Cancer Vaccine Trials | ErVimmune, a Lyon-based biotech, secured €17 million in Series A funding. This pivotal investment propels its innovative off-the-shelf cancer vaccine, ErVac01, into human clinical trials. The company pioneers therapeutic vaccines targeting ... |
| 21.01.2026 | French BioTech company ErVimmune raises €17 million to tackle hard-to-treat cancers | ErVimmune, a BioTech company out of Lyon developing cancer vaccines and cell therapies that target ‘cold tumors’ – cancers that do not respond to current immunotherapies – today announces the first closing of its €17 million ($19.8 million)... |
| 19.11.2025 | Artios Pharma Secures $115M to Advance Cancer Therapies | Artios Pharma, a UK-based biotech firm, has secured $115 million in Series D funding. The financing aims to boost the development of its precision cancer treatments. Focus on DNA damage response (DDR) is key. Funds will advance clinical tri... |
| 17.11.2025 | Artios raises $115M Series D to accelerate first-in-class cancer therapies | Biotech company Artios today announced the successful close of an oversubscribed $115 million Series D financing.
Artios is pioneering next-generation approaches in the DNA damage response (DDR) field through its comprehensive anti-cancer a... |
| 17.11.2025 | €99 million Series D fuels Artios’ expansion of precision cancer treatment pipeline | Artios Pharma Limited, a British biopharmaceutical company committed to realising the therapeutic potential of targeting the DNA damage response (DDR) in cancer, today announced the successful close of an oversubscribed €99 million ($115 mi... |
| 29.04.2025 | Artios Pharma Reports Differentiated Clinical Activity in STELLA Phase 1/2a Study for Lead Program ART0380 at the American Association for Cancer Research (AACR) Annual Meeting 2025 | CAMBRIDGE, United Kingdom and NEW YORK, April 29, 2025 – Artios Pharma Limited (“Artios”), a clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, today reported encouraging data from its ongoing ST... |
| 28.09.2021 | Artios Doses First Patient in Phase 1/2a Study of Pol? Inhibitor ART4215 | Arix Bioscience PLC (ARIX) Artios Doses First Patient in Phase 1/2a Study of Pol? Inhibitor ART4215 28-Sep-2021 / 08:15 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the c... |
| 10.08.2021 | Artios announces £110m Series C financing | Artios announces £110m Series C financing
10-08-2021
Artios Pharma Limited, a leading DNA Damage Response (DDR) company exploiting a broad DDR-based platform and small molecule drug discovery capabilities to develop a diverse pipeline of pr... |
| 28.07.2021 | UK's Artios Pharma lands $153M Series C | Biotech startup Artios Pharma has raised $153 million in a round co-led by Omega Funds and TCG X. The startup develops novel cancer treatments to target DNA damage. The capital will go toward developing its pipeline of drug candidates and f... |
| 27.07.2021 | Artios Announces $153 Million (£110 Million) Series C Financing Led by Omega Funds and TCG X | • Funding propels Artios’ ability to progress beyond synthetic lethality and to continue the exploitation of the full spectrum of oncology vulnerabilities presented by the DNA Damage Response through deployment of Artios’ DDR-based platform... |
| 27.07.2021 | Artios Pharma has completed a $153 million series C | Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company exploiting a broad DDR-based platform and small molecule drug discovery capabilities to develop a diverse pipeline of product candidates for the treatment of cancer... |
| 27.07.2021 | IP : Artios Pharma Ltd - Announces $153 Million (£110 Million) Series C Financing Led by Omega Funds and TCG X | • Funding propels Artios' ability to progress beyond synthetic lethality and to continue the exploitation of the full spectrum of oncology vulnerabilities presented by the DNA Damage Response through deployment of Artios' DDR-based platform... |
| 27.07.2021 | Artios raises USD153m in Series C financing | Arix Bioscience PLC (ARIX) Artios raises USD153m in Series C financing 27-Jul-2021 / 07:02 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. ... |
| 27.07.2021 | Artios Pharma Ltd - Announces $153 Million (£110 Million) Series C Financing Led by Omega Funds and TCG X |
• Funding propels Artios’ ability to progress beyond synthetic lethality and to continue the exploitation of the full spectrum of oncology vulnerabilities presented by the DNA Damage Response through deployment of Artios’ DDR-based platfo... |
| 27.07.2021 | Artios raises $153M to fund DNA damage repair clinical trials | Artios Pharma has raised $153 million to take its DNA damage response (DDR) pipeline deeper into the clinic. The series C positions Artios, which is run by some of the people behind pioneering DDR drug Lynparza, to test the effect of interf... |
| 27.07.2021 | Artios raises $153M to fund DNA damage repair clinical trials | Artios Pharma has raised $153 million to take its DNA damage response (DDR) pipeline deeper into the clinic. The series C positions Artios, which is run by some of the people behind pioneering DDR drug Lynparza, to test the effect of interf... |
| 27.07.2021 | Artios raises USD153m in Series C financing -2- | TCG X is a healthcare investment firm dedicated to advancing disruptive medicines and supporting companies that can improve the lives of patients. TCG X invests in both private and public companies led by exceptional entrepreneurs focused o... |
| 27.07.2021 | Artios Announces $153 Million (£110 Million) Series C Financing Led by Omega Funds and TCG X | Funding propels Artios’ ability to progress beyond synthetic lethality and to continue the exploitation of the full spectrum of oncology vulnerabilities presented by the DNA Damage Response through deployment of Artios’ DDR-based platform a... |
| 07.04.2021 | Artios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies | CAMBRIDGE, UK and NEW YORK, USA, 7 April March 2021: Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company exploiting synthetic lethality to develop a broad pipeline of precision medicines for the treatment of cancer, ... |
| 11.02.2021 | Artios Pharma Announces the Start of First Clinical Study with the Dosing of its ATR Inhibitor, ART0380, to Patients | Cambridge, UK, and New York City, USA, 11 February 2021: Artios Pharma Limited (“Artios”), a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the treatment of cancer, today announced the start... |
| 12.01.2021 | Artios Pharma Appoints Abid Ansari as Chief Financial Officer | Cambridge, UK and New York City, USA, 12th January 2021: Artios Pharma Limited (“Artios”), a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the treatment of cancer, announces the appointment... |
| 03.12.2020 | Merck KGaA and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology | Darmstadt, Germany, Cambridge, UK and New York, USA, 3rd December 2020: Merck KGaA, a leading science and technology company and Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of prec... |
| 06.11.2019 | Artios Pharma, MD Anderson and ShangPharma Announce In-Licensing Agreement for DNA Damage Response Inhibitor | CAMBRIDGE, England and HOUSTON and SOUTH SAN FRANCISCO, Calif., Nov. 6, 2019 — Artios Pharma Limited (Artios), The University of Texas MD Anderson Cancer Center (MD Anderson) and ShangPharma Innovation (ShangPharma) today announce the in-li... |
| 15.08.2018 | Artios raises $84M for developing cancer drugs targeting DNA repair pathway | Artios plans to use the money to advance development of small-molecule programs that target DNA damage response, or DDR, including a lead program targeting DNA polymerase theta. DDR is the natural process by which the DNA in cells is repair... |
| 13.08.2018 | Term Sheet — Monday, August 13 | SOLVING THE TESLA PUZZLE
Good morning, Term Sheet readers.
Paid Content A.I. is the answer to protecting your enterprise in the cloud From ExtraHop
In a Q&A style blog post, Musk answers questions such as “Why did I make a public announ... |
| 10.08.2018 | DNA Damage Response Company Artios Pharma Raises £65M in Series B | Artios Pharma, a Cambridge, UK-based DNA Damage Response (DDR) company developing innovative treatments for cancer, completed a $84m (£65m) Series B financing.
The round was led by Andera Partners (formerly EdRIP) and LSP (Life Sciences Par... |
| 10.08.2018 | Artios completes £65m Series B investment round | - |
| 10.08.2018 | Pfizer, Novartis jump into an $84M development round for UK cancer drug stars at Artios | Cancer hasn’t lost its sizzle for biotech investors.
Niall Martin
VCs at Pfizer and Novartis have jumped into an $84 million round for Artios, a Cambridge, UK-based biotech with an executive crew that played key roles in disc... |
| 10.08.2018 | Artios Pharma Ltd - Announces $84 million (£65 million) Series B Financing |
Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing innovative treatments for cancer, today announced the completion of a $84 million (£65 million) Series B financing following high interest from investo... |
| 10.08.2018 | Artios Pharma Announces $84 Million (£65 Million) Series B Financing | - |
| 02.08.2018 | Artios Pharma Announces $86 million (£65 million) Series B Financing | |
| 21.09.2016 | Artios Pharma Raises $33.2M in Series A Funding | Artios Pharma Ltd., a Cambridge, UK-based developer of novel cancer treatments targeting the DNA Damage Response (DDR), launched following a $33.2m (£25m) Series A financing.
Backers included SV Life Sciences, Merck Ventures, Imperial Innov... |
| - | Artios Pharma | “Artios is a leading independent DDR Company with a strong pipeline of novel cancer therapies in development with first-in-class & best-in-class potential.” |
| - | Artios raises $84M for developing cancer drugs targeting DNA repair pathway | A company developing cancer therapies whose mechanism of action relies on so-called synthetic lethality has drawn a new round of venture capital financing.
Based on Cambridge, UK, Artios Pharma said it raised $84 million in a Series B round... |
